Cited by 476Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsIon Channels and Receptors

The Endocannabinoid System and Pain

Open access
Guindon, Josee, Hohmann, Andrea·2009·CNS & Neurological Disorders - Drug Targets

Abstract

The therapeutic potential of cannabinoids has been the topic of extensive investigation following the discovery of cannabinoid receptors and their endogenous ligands. Cannabinoid receptors and their endogenous ligands are present at supraspinal, spinal and peripheral levels. Cannabinoids suppress behavioral responses to noxious stimulation and suppress nociceptive processing through activation of cannabinoid CB(1) and CB(2) receptor subtypes. Endocannabinoids, the brain's own cannabis-like substances, share the same molecular target as Delta(9)-tetrahydrocannabinol, the main psychoactive component in cannabis. Endocannabinoids serve as synaptic circuit breakers and regulate multiple physiological and pathological conditions, e.g. regulation of food intake, immunomodulation, inflammation, analgesia, cancer, addictive behavior, epilepsy and others. This review will focus on uncovering the roles of anandamide and 2-arachidonoylglycerol, the two best characterized endocannabinoids identified to date, in controlling nociceptive responding. The roles of anandamide and 2-arachidonoylglycerol, released under physiological conditions, in modulating nociceptive responding at different levels of the neuraxis will be emphasized in this review. Effects of modulation of endocannabinoid levels through inhibition of endocannabinoid hydrolysis and uptake is also compared with effects of exogenous administration of synthetic endocannabinoids in acute, inflammatory and neuropathic pain models. Finally, the therapeutic potential of the endocannabinoid signaling system is discussed in the context of identifying novel pharmacotherapies for the treatment of pain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/187152709789824660

Cites

255 of 255 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cannabinoid-induced antinociception is reported in a variety of preclinical inflammatory pain models, including intraplantar injection of carrageenan and LPS.

    “Cannabinoidinduced antinociception is reported in a variety of preclinical inflammatory pain models (Table 2; also see a review by Guindon and Hohmann, 2009), including intraplantar injection (that is, into the ventral footpad) of the seaweed extract carrageenan, and the Gram-negative bacterial-derived endotoxin lipopolysaccharide (LPS).”
  • Using complementary genetic and pharmacological approaches, distinct components of the endocannabinoid system (receptors and endocannabinoid-regulating enzymes) have emerged as promising targets to treat neuropathic pain.

    “Using complementary genetic and pharmacological approaches, distinct components of the endocannabinoid system (ie, receptors and endocannabinoid-regulating enzymes) have emerged as promising targets to treat neuropathic pain (Table 5; for additional information, Guindon and Hohmann, 2009;Rahn and Hohmann, 2009).”
  • The finding supports previous work demonstrating the potential of the endocannabinoid system as a target for new therapies to alleviate pain.

    “and supports a growing body of previous work in numerous contexts demonstrating the considerable potential of the endocannabinoid system as a target for the development of new therapies to alleviate pain [14,17].”

    From Endocannabinoid involvement in endometriosis. (2010) · cites this paper as [17]

  • Little is known about mechanisms by which the endocannabinoid system and exogenous cannabinoid agents act to influence pain in the specific context of endometriosis-associated pain.

    “Although mechanisms by which the endocannabinoid system and exogenous cannabinoid agents act to influence pain are under intense study [14,17], little is known in the specific context of endometriosis-associated pain.”

    From Endocannabinoid involvement in endometriosis. (2010) · cites this paper as [17]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [1]Abel EL Marijuana: The first twelve thousand years 1980 New York Plenum Press
  2. [24]Herkenham M Pertwee RG Localization of cannabinoid receptors in brain and periphery Cannabinoid receptors 1995 London Academic Press 145 166
  3. [113]Guindon J Hohmann AG Handbook of Neuroscience for the Neural and Behavioral Sciences Bernston Gary G Cacioppo John T Pain: Mechanisms and Measurement 2009 New Jersey John H. Wiley & Sons in press

Cited by

Sorted by citations

Authors
Guindon, J., & Hohmann, A.
Affiliations
University of Georgia (US)
Corresponding author
Hohmann, Andrea
Venue
CNS & Neurological Disorders - Drug Targets
Published
2009-12-01
Volume
8
Issue
6
Pages
403-421
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2054998310
Cited by
476
References
255
Citations by year
2026: 21 · 2025: 19 · 2024: 36 · 2023: 27 · 2022: 41 · 2021: 38 · 2020: 23 · 2019: 25 · 2018: 33 · 2017: 27 · 2016: 23 · 2015: 23 · 2014: 39 · 2013: 28 · 2012: 36
FWCI
17.25
Type
journal article
Language
en
Open access
Locations
  • CNS & Neurological Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (DA022478, DA-022702, R21DA022478, R01DA021644, R21DA022702, DA021644)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
Keywords
endocannabinoid system, pain, anandamide, 2-arachidonoylglycerol, cannabinoid receptors, CB1 receptor, CB2 receptor, nociception, analgesia, neuropathic pain, inflammatory pain, synthetic cannabinoids, pharmacological pain management
MeSH terms
Animals, Arachidonic Acids, Brain, Glycerides, Humans, Pain, Receptors, Cannabinoid, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review